CannEpil

CannEpil
Product Description

CannEpil®, one of Argent BioPharma's flagship products, is an enhanced iteration of a compounded isolated cannabinoid formulation. It leverages well-known historical data to become one of the first compounded prescription investigational drugs used for seizure management over the past years. The active ingredients in this formulation include two isolated cannabinoids, each dissolved in a liquid solution

Read more Show less

Argent BioPharma ltd

  • Country/Region:
    United Kingdom
  • On CPHI since:
    2024
  • Certificates:
    1
  • Employees:
    50 - 99
Company types
Biopharmaceutical company
CMO/CDMO
OTC
Pharmaceutical company
Start-up
Primary activities
API Producer
Biopharmaceutical
Custom Manufacturing/Custom Synthesis
OTC
View company profile
Categories
more categories Show less
Specifications
  • Details
    Early clinical data has been accrued from the experience using CannEpil for treatment of epilepsy through Australia’s Special Access Scheme program and the Irish Medicinal Cannabis Access Program (MCAP). Two pivotal findings have been made during this early experience:
    CannEpil was prescribed at 28-35% lower doses compared to the CBD-only drug to which it was compared, demonstrating its potent efficiency.
    The retention time, or the continued prescription rate, for CannEpil was observed to be higher than that of the CBD-only counterpart, possibly indicating an improved safety profile in addition to enhanced efficacy.

  • Supplied from
    Slovenia
More specifications Fewer specifications
Sales Markets
Show more Show less

Argent BioPharma ltd

  • Country/Region:
    United Kingdom
  • On CPHI since:
    2024
  • Certificates:
    1
  • Employees:
    50 - 99
Company types
Biopharmaceutical company
CMO/CDMO
OTC
Pharmaceutical company
Start-up
Primary activities
API Producer
Biopharmaceutical
Custom Manufacturing/Custom Synthesis
OTC
View company profile

More Products from Argent BioPharma ltd (2)

  • CimetrA®

    Product CimetrA®

    Early Stage Revenue Generating Immunomodulation Treatment for ARDS CimetrA® delivered 50,000 units to the USA market (Under Special Access) and over 100,000 worldwide, representing over US$2,500,000 in sales to date. Results of Preclinical and Clinical program, meeting FDA guidelines, to date: • Demon...
  • IrniCann®

    Product IrniCann®

    Pre-Clinical Stage Glioblastoma • Innovative pre-clinical stage drug targeting Glioblastoma Multiforme (GBM) Stem Cells, one of the deadliest forms of brain cancer, with the potential to transform treatment outcomes for this aggressive disease​ • An estimated 250,000 new cases of GBM per year worldwide....

Argent BioPharma ltd resources (1)